WASHINGTON, March 13 (TNSFR) -- The Food and Drug Administration (FDA) has announced the reopening of the comment period for the draft guidance titled "E6(R3) Good Clinical Practice: Annex 2," originally published on December 30, 2024. The decision comes in response to requests for additional time to provide feedback on the document, which outlines updated considerations for clinical trial design and conduct. Interested parties now have until March 31, 2025, to submit comments before t . . .

Click here for more information about our products